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 1. ABSTRACT 
 Objective. Ovarian clear cell carcinoma (OCCC) is an aggressive ovarian 
cancer with a higher frequency in Japan and often becomes chemorefractory disease. 
Reliable genetic diagnosis is essential to affirm the success of precision medicine for 
OCCC treatment. The aim of this study is, therefore, to identify novel mutations in 
OCCCs and develop a feasible clinical next generation sequencing (NGS) approach 
using formalin-fixed paraffin-embedded (FFPE) rather than preferable but not always 
available fresh frozen (FF) samples. 
 Methods. We optimized and evaluated exome analyses of 409 cancer-related 
genes using FFPE and FF DNA and analyzed NGS data to identify somatic mutations in 
Japanese OCCCs. 
 Results. Sufficient and good quality DNAs from FFPE samples were extracted 
from 18 (FIGO Stage I: 12) out of 29 pairs of matched normal and OCCC for NGS 
(63%). The fine quality of extracted DNAs depended on the length of storage period 
(less than 2 years storage was better quality). We also identified 45 somatic mutations in 
34 genes including unreported variants from those FFPE DNA, in which somatic 
mutations in the PIK3CA gene were the most common (28%) as previously reported. 
Seven genes (PIK3CA, ARID1A, CTNNB1, CSMD3, LPHN3, LRP1B, and TP53) were 
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mutated in at least two independent OCCCs. CSMD3, LPHN3, and LRP1B have not 
been reported in OCCC. FF samples from 3 out of those 18 OCCCs were available and 
13 out of 14 FFPE somatic mutations were concordant. 
 Conclusions. We successfully identified novel genetic alterations in Japanese 
OCCCs and demonstrated a feasible clinical diagnostic procedure using targeted NGS 
for OCCC FFPE samples. 
 
Key words: Somatic mutations, Next-generation sequencing, Clinical sequencing, 
FFPE, Ovarian clear cell carcinoma. 
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2. INTRODUCTION 
Ovarian carcinoma (OC) is the most devastating malignant gynecological 
tumors. In the United States, 21,290 new cases and 14,180 deaths were estimated in 
2015 [1]. Hence, it has been dubbed the “Silent Killer”, since it is difficult to diagnose 
and treat in its early stage due to the lack of obvious symptoms. Although many surgical 
techniques and chemotherapies have been developed, 5 year survival rate for OC is 44% 
[2, 3].  
About 90% of primary OCs are epithelial carcinomas and are divided into 4 
major histological types: serous, mucinous, endometrioid, and clear cell. Recently, 
ovarian epithelial carcinoma is classified into 2 broad simplified categories. Type I 
includes low-grade serous, endometrioid, clear cell, mucinous, and transitional cell 
carcinomas based on the histopathology and genomic studies, while high-grade serous 
carcinomas, undifferentiated carcinomas, and carcinosarcomas belong type II [4]. 
Ovarian clear cell carcinoma (OCCC) is the type I tumor, but nevertheless showed 
unfavorable prognosis when diagnosed at an advanced stage because of poor response 
rates to platinum-based chemotherapy [5, 6]. There is a considerable geographical 
variation in OCCC incident rates and prevalence; 1-12% of OC in Europe and the 
United States is OCCC, while 15-25% in Japan [4, 7-9]. Endometriosis is a risk factor 
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for OCCC. Nevertheless, OCCCs do not express estrogen or progesterone receptors, 
therefore a hormone independent during the transformation process. [9] Although little 
is known about the pathogenesis of OCCC, frequent somatic mutations of the AT rich 
interactive domain 1A (SWI-like) (ARID1A) [10, 11] and phosphatidylinositol-4, 
5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) genes [12] have been 
reported. Cancer therapy continues its shift towards molecular target agents and 
increasingly individually tailored regimens. Therefore patient’s precise genetic 
information is increasingly important for individualized treatment toward ‘precision 
medicine’. Recent advances in next-generation sequencing (NGS) allow cancer patients 
to gain access to the genetic profiling of their cancers and to identify many novel 
mutations including actionable therapeutic targets.  
DNA extracted from fresh frozen (FF) samples is generally used for NGS 
analysis for genetic profiling of cancer and provides a typically high quality DNA 
fragments for NGS sequencing. However, FF samples may not be available for all 
cancer patients, while formalin-fixed paraffin-embedded (FFPE) samples are currently 
the most widely available specimen for general clinical set-ups besides 
cost-effectiveness. Furthermore FFPE samples along with histopathological evaluation 
allow to analyze intra-tumor genetic diversity and tumor heterogeneity. One major 
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limitation to use DNA from routinely prepared FFPE samples may be a poor quality of 
the extracted DNA comparing with FF samples, which is more suitable for basic 
research. NGS analysis using FFPE samples have been reported successfully in 
gastrointestinal tract [13], bladder [14], prostate [15], and lung [16] cancers.  
Herein, we successfully optimized each step condition for FFPE-based NGS 
procedures targeting 409 cancer-related genes and showed analogous results between 
the analyses using the FFPE and the FF. We detected known somatic mutations, as well 
as some novel mutations, and its intratumoral genetic heterogeneity, confirming the 
reasonable compatibility with previous studies, although there exist ethnic/racial 
disparities in the prevalence of OCCC. 
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3. MATERIALS AND METHODS 
3.1. Patients and pathological materials 
 This study was approved by the ethics committee of the Chiba Cancer Center, 
Chiba, Japan (Institutional Review Board approval number 24-92). Twenty nine patients 
with histologically confirmed OCCC were used from archives in the division of surgical 
pathology in Chiba Cancer Center (Table 1). None of them had undergone 
chemotherapy or radiation therapy before surgery. Adequate FFPE blocks that contain 
sufficient amount of cancer cells in pathological specimens confirmed by the 
Hematoxylin & Eosin stain and immunohistochemical stainings were selected before 
the tissue dissection. Ten FFPE serial sections of 6 m thickness per sample for tumor 
and normal tissues were used. However, many FFPE samples exhibit high degrees of 
tumor heterogeneity, with varied admixture of reactive stroma, inflammatory cells and 
necrosis. We performed macrodissection to enrich tumor cells on FFPE serial sections 
(> 80% tumor cells) (Figure 1). Furthermore FF samples from 3 patients were available 
and subjected to NGS analysis to assess the feasibility of FFPE-based NGS. 
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3.2. The quality assessment of DNA extracted from FFPE samples  
 DNA was extracted from FFPE samples using the QIAmp DNA FFPE Tissue 
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Quality 
and quantity of DNA were assessed using Nano-Drop ND-1000 Spectrophotometer 
(Nano Drop Technologies, Wilmington, DE), agarose gel electrophoresis and 
quantitative polymerase chain reactions (qPCR). qPCR was conducted with 5 ng and 20 
ng of template DNAs using the FFPE DNA QC Assay (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA). Briefly, a 256 bp fragment DNA was amplified by PCR 
using forward primer of 5'-AGCTGAGTGCGTCCTGTCACT-3' and reverse primer of 
5'-ACCTCACCTCAGCCATTGAACT-3' adding Taq Man Gene Expression Master Mix 
(Thermo Fisher Scientific) according to the manufacturer’s instructions. TaqMan MGB 
Probe (FAM) used was 5'-CACTCCCATGTCCC-3'. If after determination of DNA 
amount measured by Nano-Drop-1000 Spectrophotometer either 5 ng or 20 ng of 
template DNAs passed quality assessment by qPCR (the cut-off value of > 0.3), the 
NGS analysis was performed. This cut-off value was determined by our previous 
experiments that relative value of > 0.3 resulted in successful NGS analysis 
(unpublished data). 
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3.3. Library preparations 
 Library preparation for the 409 gene panel was performed using the Ion 
AmpliSeqTM Comprehensive Cancer Panel (CCP) (Thermo Fisher Scientific). The panel 
was designed to facilitate targeted amplification-based capture and sequencing of 
coding regions of 409 cancer-related genes. It includes 4 primer pools with 
approximately 4000 primer pairs in each pool and requires a total of 40-80 ng of DNA 
as a template for each sample (10-20 ng per pool) in this study. Library preparations for 
each sample were performed using the CCP, the Ion AmpliseqTM Library Kit 2.0-96LV, 
the Ion Xpress Barcode Adaptors 1-96 Kit (Thermo Fisher Scientific), and the 
Agencourt AMPure XP reagent (BD Biosciences, Franklin Lakes, NJ, USA). The 
library was then quantified using the Ion Library Quantitation Kit (Thermo Fisher 
Scientific). On the basis of these results, the library was diluted to 8 pM. 
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3.4. Emulsion PCR and enrichment 
 The clonal amplification of barcoded DNA library onto ion spheres (ISPs) was 
carried out using emulsion PCR (Ion PITM Template OT2 Kit v3) in the Ion One 
TouchTM 2 instrument (Thermo Fisher Scientific). Ratio of imputed library of tumor to 
normal was set at 3 to 1 (simultaneously 3 pairs in 1 run). Following emulsion PCR and 
recovery, isolation of amplified templates on ISPs was performed using the Ion One 
TouchTM ES (Thermo Fisher Scientific).  
 
3.5. Sequencing and mutation analysis 
 Targeted sequencing of 409 cancer-related genes was performed on ion torrent 
Ion Proton sequencer (Thermo Fisher Scientific). Briefly, the barcoded libraries were 
loaded into the Ion PITM Chip v2 (3 samples per chip) using the Ion PITM Sequencing 
200 Kit v3 according to manufacturer’s instructions. Subsequently, the Ion PITM chip 
was analyzed by Ion Proton sequencer. The Torrent Suite software was used to parse a 
barcoded read, to align to the human reference genome (hg19), and to generate run 
metrics, including chip loading efficiency, total read counts, and quality. Variant Caller 
v4.0.2 software was used for variant detection. All variants were annotated ANNOVAR. 
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3.6. Identification of somatic variants  
 A number of steps were used to filter nucleotide variants identified in the 
screening; (1) nonsynonymous and nonsense single nucleotide variants and (2) tumor 
specific somatic mutations with variant allele frequencies of > 10%. Furthermore 
variants were observed using the Integrated Genomics Viewer, which can visualize the 
read alignment and the presence of variants to exclude sequencing errors. 
 
3.7. Validation using Sanger sequencing 
 Somatic mutations with variant allele frequencies > 15% were validated using 
the Sanger sequencing method account for primer setting and performance of Sanger 
sequencing. Sanger sequencing was performed on an Applied Biosystems 3730 DNA 
analyzer (Applied Biosystems, Foster City, CA, USA) and sequences were analyzed 
with Sequencing Analysis software 6 (Applied Biosystems). 
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4. RESULTS 
4.1. Eighteen pairs of DNA from FFPE samples passed quality check 
 DNA was extracted from 58 FFPE blocks of 29 cases diagnosed with OCCC. 
Details of the storage period of the FFPE block were as follows: 36-48 months in 1 
cases, 24-36 months in 8 cases, 12-24 months in 5 cases, and 1-12 months in 15 cases. 
DNAs extracted from those FFPE samples were checked by a standard qPCR procedure 
creating a 256 bp product. DNA quality of each paired sample was similar. Eighteen 
cases (63%) passed a quality check of relative value 0.3. DNA extracted from FFPE 
samples preserved for a shorter time period showed better quality. Eighteen cases: 1 out 
of 8 cases for the storage period of 24-36 months, 4 of 5 cases for 12-24 months, and 13 
out of 15 cases for 1-12 months, passed the quality check and were subjected to the 
subsequent NGS analysis. In terms of fixation time, 40% of cases fixed for over 24 h 
passed quality, while 67% for < 24 h passed (Figure 2, Table 2).  
 
4.2. Clinico-pathological features of 18 cases  
 Of 18 cases (range, 41 to 71 years and Median 55), all are unilateral ovarian 
tumors (nine right, nine left) and 16 were diagnosed with clear cell adenocarcinoma, 1 
was clear cell adenocarcinofibroma, and 1 was mixed epithelial tumor (clear cell and 
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endometrioid adenocarcinoma). The international clinical staging system by Federation 
of Gynecology and Obstetrics (FIGO) was used and 12 cases were diagnosed stage I 
(66%); 3 for stage II (17%); 2 for stage III (11%); and 1 for stage IV (6%). Thirteen out 
of 18 cases (72%) manifested endometoriosis (Table.1). 
 
4.3. Forty five out of 92 candidate somatic mutations were detected  
 A total of 92 candidate somatic mutations in 65 genes with variant allele 
frequencies of > 10% were identified from 18 OCCCs by NGS analysis. We performed 
validation by Sanger sequencing for 58 of them with variant allele frequencies of > 15%. 
Forty (69%) of these 58 somatic mutations were concordant between NGS and Sanger 
sequencing. The rest of 18 discordant somatic mutations fall in two categories; (1) 
number of coverage reads of normal tissues was < 20 reads, (2) number of coverage 
reads of normal tissues was > 20 reads but distance from amplicon boundaries to variant 
position was < 6 bp (Figure 3a). Thus we optimized the filtering of NGS data as 
follows: coverage of normal tissue is > 20 reads and amplicon boundaries from the 
variant is > 6 bp. After applying this filtering of the somatic mutations with variant 
allele frequencies of 10 to 15%, 5 somatic mutations were filtering out (Figure 3b). 
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Finally, a total of 45 somatic mutations in 34 genes were considered to be somatic 
mutations in OCCCs. 
 
4.4. Characteristics of somatic mutations in 18 Japanese OCCCs  
 Average number of somatic mutations identified in each tumor was 2.5 
alterations (range, 1 to 6). A total of 7 genes were mutated in multiple OCCC cases: 5 in 
PIK3CA (28%), 3 in ARID1A, and 2 in catenin, beta 1 (CTNNB1), CUB and Sushi 
multiple domains 3 (CSMD3), latrophilin 3 (LPHN3), low-density lipoprotein receptor 
related protein 1B (LRP1B), or tumor protein p53 (TP53). The number of mutations in 
each case was not associated with FIGO staging, age and endometriosis. C to T 
transition was the most frequent substitution mutations in 45 somatic mutations (Figure 
4). Furthermore functional analysis by GeneMANIA identified 83 functions using the 
false discovery rate of < 0.05. Among these, the top 5 functions were 
phosphatidylinositol 3-kinase (PI3K) activity/phosphatidylinositol-mediated pathway 
(mutated in 6 cases, 33% [PIK3CA, v-erb-b2 avian erythroblastic leukemia viral 
oncogene homolog 2 (ERBB2), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
subunit gamma (PIK3CG), phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2), 
phosphatase and tensin homolog (PTEN)]), fibroblast growth factor receptor signaling 
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pathway (8 cases, 44% [PIK3CA, CTNNB1, ERBB2, PIK3R2, PTEN, protein 
phosphatase 2, regulatory subunit A, alpha (PPP2R1A)]), chromatin remodeling (3 
cases, 17% [ARID1A, SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 (SMARCA4)]), Fc receptor signaling pathway (6 
cases, 33% [PIK3CA, ERBB2, PIK3R2, PTEN, wiskott-aldrich syndrome (WAS)]), and 
epidermal growth factor receptor signaling pathway (6 cases, 33% [PIK3CA, ERBB2, 
F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase (FBXW7), 
PIK3R2, PTEN]) pathways. At least one of each aberration of these five functions was 
seen in 12 out of 18 OCCCs (67%). 
 
4.5. Eleven known somatic mutations and 7 novel somatic mutations were 
identified across 7 genes that harbor somatic mutations in multiple OCCC cases 
 Three somatic mutations of ARID1A were nonsense mutations (p.Q464X, 
p.Q566X, and p.Q601X). Fifteen non-synonymous mutations in 6 genes were further 
analyzed for functional prediction of amino acid changes using the Protein Variation 
Effect Analyzer (PROVEAN). PROVEAN Genome Variants of PROVEAN tool 
calculates PROVEAN-score (cut-off=-2.5) and SIFT-score (cut-off=0.05). Eight out of 
15 mutations were evaluated to deleterious in PROVEAN and damaging in SIFT. In 
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these 15 somatic mutations, 9 mutations were reported in the Catalogue of Somatic 
Mutations in Cancer (COSMIC) database: PIK3CA (p.M1004I, p.E545G. p.H1047R, 
p.E542K, and p.V346G), CTNNB1 (p.S33C and p.S37C), TP53 (p.R43H and p.E11K) 
and some were overlapping with functional prediction. Six somatic mutations were 
found in the Single Nucleotide Polymorphism Database (dbSNP): PIK3CA (p.E545G, 
p.H1047R, and p.E542K), CTNNB1 (p.S33C and p.S37C), TP53 (p.R43H). Out of 7 
somatic mutations that were not previously enrolled in COSMIC database or dbSNP, 5 
mutations affecting CSMD3 (p.R1021H and p.L1828V), LPHN3 (p.E223K and 
p.L1039I) and ARID1A (p.Q601X) were predicted to alter physiological function of the 
gene products, while the other 2 mutations affecting LRP1B (p.I2759M and p.R151K) 
were not (Table 3). 
 
4.6. NGS analyses using FFPE and FF samples demonstrated highly concordant 
results  
 NGS analyses using 3 paired FFPE and FF samples under our optimized 
conditions demonstrated highly concordant results (93%). Not only identified genes but 
also variant allele frequency was similar between two analyses. On the other hand, 
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somatic mutation of APC membrane recruitment protein 1 (AMER1) was only identified 
from FFPE sample #12, but not in FF analysis of the same sample (Figure 5). 
 
4.7. Tumor heterogeneity was uncovered by FFPE-based NGS analysis 
 To verify tumor heterogeneity by FFPE-based NGS, we compared 
histologically distinct lesions in the same patient. Of 2 lesions with variable 
morphologies of OCCC, one lesion was composed of tumor cells with abundant 
basement membrane like material and harbored CTNNB1 (p.S37C) mutation, while the 
other region was solid growth pattern and harbored CTNNB1 (p.S37C) as well as 
LPHN3 mutation (p.E223K) (Figure 6a, b). In a case of mixed epithelial tumors, 2 
somatic mutations of CTNNB1 (p.S33C) and p21 protein (Cdc42/Rac)-activated kinase 
3 (PAK3) (p.P517S) were identified in both clear cell adenocarcinoma and endometrioid 
adenocarcinoma components, whereas somatic mutation of TP53 (p.R43H) was 
identified only in clear cell adenocarcinoma component (Figure 6c, d). The AMER1 
mutation only in FFPE sample #12 could also indicate tumor heterogeneity (Figure 5).  
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5. DISCUSSION 
 In our best knowledge, this is the first report of a comprehensive mutation 
search on Japanese FFPE OCCC samples using semiconductor sequencer (Ion Proton) 
targeting 409 cancer related genes. DNA extracted from short-term stored FFPE 
samples (< 2 years) was generally feasible for NGS.  Effect of length of the storage 
period of FFPE is however controversial. Schwiger et al. reported that it is a minor 
influence on sequencing quality [17], while Hedegaard et al. reported that longer storage 
time resulted in a decreased fraction of mapped reads, increased fraction of 
non-perfectly mapped reads and reads mapping with unaligned ends [18]. Our results 
suggested that the storage time of FFPE samples has been influenced on quality of DNA 
and NGS analysis. Although storage conditions (temperature, humidity and exposure of 
sun or light) of FFPE samples might affect, basic clinical set up of our examined 
procedure without any special process for molecular analysis, therefore, can be applied 
any standard hospitals. Furthermore, we suggested that desirable fixation time could be 
< 24 h. Candidate somatic mutations identified by NGS analysis were confirmed by 
Sanger sequencing and/or optimized filtering to minimize false positive calls. The 
filtering from all variants calls in NGS data is practical avoiding time-consuming and 
expensive processes of Sanger sequencing validation. Although such a FFPE-based 
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NGS is needed for clinical settings of certain hospitals, of course, accreditation is 
important for clinical application and certification of International Organization for 
Standardization should be applied to clinical sequencing.  
  The most frequent mutated gene identified in this study was the PIK3CA gene 
(28%: 5/18), which encodes the catalytic subunit p110a of PIK3 and is located on 
chromosome 3q26.3. Both somatic mutations and gene amplification of PIK3CA 
increase PI3K activity and activate the downstream Akt signaling pathway. Kuo, et al. 
showed that somatic activating mutations PIK3CA were frequently observed in OCCC 
(33%) [12]. Furthermore we identified somatic mutations of PIK3CG, a class I catalytic 
subunit of PI3K and PIK3R2, class IA PI3K regulatory isoforms. The other six multiple 
mutated genes (ARID1A, CTNNB1, CSMD3, LPHN3, LPR1B, and TP53) were 
identified. ARID1A is a key component of the SWI/SNF chromatin-remodeling complex 
that is conserved in all eukaryotes, plays important role in controlling gene expression 
and is critical in development, differentiation, and tumor suppression [19]. Although 
46% and 57% of frequent somatic mutations of ARID1A in OCCC have been published 
recently by whole-transcriptome and exome sequencing analyses, respectively [10, 11], 
it was 17% in this study. Mutation of SWI/SNF related gene SMARCA4 was identified 
in one case, hence other genes in the ARID1 pathway may be mutated in the rest of 
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cases. Coexistence of PIK3CA and ARID1A mutations has been reported to contribute to 
ovarian clear cell tumorigenesis [20, 21], whilst it was only one case in this study. These 
differences might be explained by several factors such as tumor heterogeneity, 
sequencing methods, and enrolled population. Recently, Er TK, et al. reported that the 
most frequently mutated genes in 10 Taiwanese endometriosis-associated ovarian cancer 
(EAOC) patients were PIK3CA (6/10) and ARID1A (5/10) by the same deep sequencing 
method. In this study, 8 OCCCs were analyzed and found PIK3CA (4/8) and ARID1A 
(4/8) mutations [22] and discussed one hypermutated phenotype. We found the mutation 
frequency of PIK3CA and ARID1A in EAOC cases was 3/13 and 3/13, respectively.  
This can be partially explained by no hypermutated phenotype in this study. CTNNB1 
mutation was observed in a mixed epithelial tumor patient (clear cell adenocarcinoma 
and endometrioid carcinoma). McConechy, et al. showed that frequency of CTNNB1 
mutations is 53% in low-grade ovarian endometrioid carcinoma [23]. Endometriosis is 
associated with the development of ovarian low-grade endometrioid carcinoma and also 
plays an important role in risk and pathogenesis of OCCC [24, 25]. TP53, one of the 
most frequently mutated genes in carcinoma, was also mutated in OCCC [26]. Clear cell 
carcinomas can arise in the ovary and the uterus, and show histological and biological 
similarities across sites. There are, however, some apparent differences between OCCC 
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and endometrial clear cell carcinoma (ECCC). Based on previous reports, ARID1A 
protein loss and PIK3CA mutations are observed in approximately 23% and 9% of 
ECCC, respectively [27, 28]. PI3K/AKT/mTOR signaling and chromatin remodeling 
pathways must be major functional pathways of OCCC carcinogenesis [29], which is 
also observed in this study. Somatic mutations of CSMD3, LPHN3, and LRP1B have not 
been reported in OCCC, which have been associated with tumorigenesis and 
chemoresistance. Thus, further functional analysis including recent advances of 
organoid and gene editing technologies shall be needed to identify the functional role of 
those mutation on OCCC carcinogenesis [30-33]. Genetic diagnosis of OCCC is also 
important to select molecular targeted therapies, such as mTOR inhibitor [34] and 
synthetic lethality of ARID1A [35].  
  Recent reports suggested that not only pathway signature but also mutation 
signature is important to recapitulate carcinogenesis in individual cancer [36]. Our 
results showing C to T transition was most frequently observed (53.3%) as seen in the 
type 1B category and interestingly, type 3 next to type 1B is associated with breast 
cancer 1/2, early onset (BRCA1/2) mutations. Because high-grade serous 
adenocarcinoma is associated with BRCA1/2 mutations and the expression profile of 
high-grade serous adenocarcinoma differ from the expression profile of OCCC [37, 38], 
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type 3 might correspond to high-grade serous adenocarcinoma. Although there have 
been reported that formalin fixation associated with artificial C to T transition and might 
make a bias of subsequent sequencing results [39, 40], there was almost no difference in 
the frequency of C to T transitions between FF- and FFPE-based NGS data. Although a 
T to G substitution mutation, not C to T transitions, in the AMER1 gene was identified 
only from FFPE sample, this is unlikely to be artificial but rather reflects tumor 
heterogeneity. Therefore, FFPE samples showed high concordance with FF samples. 
For better understanding of tumor heterogeneity, detailed analysis of histomorphology, 
immunophenotype, and genetic alterations from multiple legions should be employed to 
perform the companion diagnosis to treat, care and/or manage each OCCC patient. In 
this respect, genetic analysis from FFPE samples is a suitable approach to understand 
tumor heterogeneity of patients [13-15]. We also showed mutational heterogeneity 
within a tumor using DNAs obtained from different dissected samples. 
  In summary, we successfully established an optimized clinical molecular 
diagnosis procedure in OCCC using FFPE-based NGS of 409 cancer-related genes and 
identified 45 somatic mutations in 34 genes in Japanese women (Table 4, Figure 4). Not 
only pathological diagnosis but also subclassification of OCCC based on a large-scale 
analysis of genetic variation and biological function prediction is essential for 
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adequately predicting response to therapy in patients, its tumor behavior, origin, and 
carcinogenesis. Although further improvement of FFPE-based NGS methods are 
required, clinical sequencing using FFPE samples which is widely used pathological 
diagnosis will be a powerful and essential tool for clinical molecular diagnosis in 
medical diagnostic laboratories. 
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Table 1
Table 1 Clinico-pathologic features of enrolled 29 OCCC cases and 18 cases which passed DNA 
quality control testing
Characteristics
Data
All QC passed
Number of cases 29 18
Median age (range) 54 (40-74) 55 (41-71)
Site of primary tumor, right/left 16/13 9/9
Histological diagnoses
Clear cell adenocarcinoma 26 16
Clear cell adenocarcinofibroma 1 1
Clear cell adenocarcinoma + Endometrioid adenocarcinoma 2 1
Lymph node metastasis, with/without/unknown 2/25/2 2/15/1
Endometriosis, with/without 19/10 13/5
FIGO staging
I 20 12
II 3 3
III 3 2
IV 3 1
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Table 2
Table 2 Clinico-pathologic features of 29 OCCCs and summary of somatic mutations identified from 18 OCCCs sequenced by the NGS analysis
Case 
No. Age Endometriosis
Tumor 
Site
FIGO 
staging
TNM 
stage Histology
Fixation 
time
Storage time 
points of FFPE QC
NGS 
No.
Somatic mutations identified 
(nonsynonymous) Prognosis
1 40 Yes Right IV T2cN0M1 CCC+EMC Over 24 h 36-48 months Not passed Dead
2 66 No Left Ia T1aN0M0 CCC <  24 h 24-36 months Not passed Alive
3 52 Yes Right Ia T1aN0M0 CCC < 24 h 24-36 months Not passed Dead
4 59 No Right Ic T1cN0M0 CCC < 24 h 24-36 months Not passed Alive
5 52 Yes Left Ic T1cN0M0 CCC < 24 h 24-36 months Not passed Alive
6 47 No Left Ia T1aN0M0 CCC Over 24 h 24-36 months Not passed Alive
7 73 Yes Left Ia T1aN0M0 CCC < 24 h 24-36 months Not passed Alive
8 74 No Right IIIb T3bN0M0 CCC < 24 h 24-36 months Not passed Dead
9 60 Yes Left Ia T1aN0M0 CCC < 24 h 24-36 months Passed #9 PKHD1, CRTC1 Alive
10 51 Yes Right IV T1aN1M1 CCC Over 24 h 12-24 months Not passed Alive
11 69 No Right IIc T2cN0M0 CCC Over 24 h 12-24 months Passed #3 BCL6, ETS1, WAS Alive
12 52 Yes Left Ic T1cN0M0 CCC+EMC < 24 h 12-24 months Passed #4 CTNNB1, TP53, PAK3 Alive
13 63 No Right Ia T1aN0M0 CCC < 24 h 12-24 months Passed #5 MDM4, PIK3CA Alive
14 44 Yes Right IIIc T1aN1M0 CCCF < 24 h 12-24 months Passed #6 PDE4DIP, TP53 Alive
15 56 Yes Right Ia T1aN0M0 CCC < 24 h 1-12 months Not passed Alive
16 69 No Right Ic T1cN0M0 CCC < 24 h 1-12 months Not passed Alive
17 71 Yes Left IIc T2cN0M0 CCC < 24 h 1-12 months Passed #1 SYNE1, PIK3CG Alive
18 55 Yes Right Ia T1aN0M0 CCC < 24 h 1-12 months Passed #2 NFE2L2, PTCH1 Alive
19 56 No Right Ia T1aN0M0 CCC < 24 h 1-12 months Passed #7 LRP1B, SF3B1, LIFR Alive
20 46 No Left IV T1cN1M1 CCC < 24 h 1-12 months Passed #8 BAI3 Alive
21 57 Yes Left Ic T1cNxM0 CCC < 24 h 1-12 months Passed #10 CSMD3 Alive
22 53 Yes Left Ic T1cN0M0 CCC Over 24 h 1-12 months Passed #11 PIK3CA Alive
23 54 No Left IIIa T3aN0M0 CCC < 24 h 1-12 months Passed #12 MAG1, PIK3CA, CSMD3, TLR4, PIK3R2, AMER1 Alive
24 41 Yes Right IIc T2cN0M0 CCC < 24 h 1-12 months Passed #13 FBXW7 Alive
25 45 Yes Right Ic T1cN0M0 CCC < 24 h 1-12 months Passed #14 ARID1A, LRP1B, SMARCA4, PPP2R1A Alive
26 56 Yes Right Ia T1aN0M0 CCC < 24 h 1-12 months Passed #15 CTNNB1, LPHN3 Alive
27 50 Yes Right Ic T1cN0M0 CCC < 24 h 1-12 months Passed #16 ARID1A, PIK3CA, DST, NUMA1, ERBB2 Alive
28 51 Yes Left Ic T1cN0M0 CCC < 24 h 1-12 months Passed #17 ARID1A, LPHN3, KDM5C Alive
29 61 Yes Left Ia T1aN0M0 CCC < 24 h 1-12 months Passed #18 PIK3CA, PTEN Alive
CCC, clear cell adenocarcinoma; CCCF, clear cell adenocarcinofibroma; EMC, endometrioid adenocarcinoma
32
Table 3
Table 3 A total of 7 genes were mutated in multiple OCCC cases
Sample 
no. Gene Position Ref Alt
Type of 
alteration NM number
Protein 
change
Var 
(%) Reads
Provean
Prediction
SIFT 
Prediction dbSNP ID COSMIC ID
#5 PIK3CA chr3:178951957 G A Missense NM_006218 p.M1004I 32 3842 Deletrious Damaging COSM1420934
#11 PIK3CA chr3:178936092 A G Missense NM_006218 p.E545G 20 2007 Deletrious Damaging rs121913274 COSM764
#12 PIK3CA chr3:178952085 A G Missense NM_006218 p.H1047R 46 102 Neutral Damaging rs121913279 COSM775
#16 PIK3CA chr3:178936082 G A Missense NM_006218 p.E542K 27 1643 Neutral Damaging rs121913273 COSM760
#18 PIK3CA chr3:178921555 T G Missense NM_006218 p.V346G 23 120 Deletrious Damaging COSM4714415
#14 ARID1A chr1:27057682 C T Nonsense NM_139135 p.Q464X 55 1053 NA NA COSM5347142
#16 ARID1A chr1:27057988 C T Nonsense NM_139135 p.Q566X 41 215 NA NA COSM1296220
#17 ARID1A chr1:27058093 C T Nonsense NM_139135 p.Q601X 90 176 NA NA
#4 CTNNB1 chr3:41266101 C G Missense NM_001098210 p.S33C 45 1067 Deletrious Damaging rs121913400 COSM5677
#15 CTNNB1 chr3:41266113 C G Missense NM_001098210 p.S37C 39 810 Deletrious Damaging rs12193403 COSM5679
#10 CSMD3 chr8:113662521 C T Missense NM_198123 p.R1021H 58 4830 Deletrious Damaging
#12 CSMD3 chr8:113421175 A C Missense NM_198123 p.L1828V 30 1584 Deletrious Tolerated
#15 LPHN3 chr4:62598744 G A Missense NM_015236 p.E223K 37 1460 Deletrious Damaging
#17 LPHN3 chr4:62863907 C A Missense NM_015236 p.L1039I 41 225 Neutral Damaging
#7 LRP1B chr2:141267618 T C Missense NM_018557 p.I2759M 23 130 Neutral Tolerated
#14 LRP1B chr2:142012102 C T Missense NM_018557 p.R151K 10 516 Neutral Tolerated
#4 TP53 chr17:7578406 C T Missense NM_001126115 p.R43H 10 1986 Deletrious Damaging rs28934578 COSM99023
#6 TP53 chr17:7579882 C T Missense NM_001126112 p.E11K 40 2495 Neutral Damaging COSM3820734
Var (%): variant allele frequency
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Table 4 Summary of 45 somatic mutations in 34 genes were identified in 18 OCCCs
Sample 
no. Gene Position Ref Alt
Type of 
alteration NM number
Protein 
change
Var 
(%) Reads
Provean
Prediction
SIFT 
Prediction dbSNP ID COSMIC ID
#1 SYNE1 shr6:152469215 T G Missense NM_033071 p.K8243T 48 2714 Neutral Tolerated
#1 PIK3CG chr7:106545584 C T Missense NM_001282426 p.R1021C 40 5441 Deletrious Damaging COSM5698913
#2 NFE2L2 chr2:178098800 T C Missense NM_006164 p.E82G 10 5067 Deletrious Damaging COSM132853
#2 PTCH1 chr9:98220390 G A Missense NM_001083602 p.R959C 29 2538 Deletrious Damaging
#3 BCL6 chr3:187447314 G C Nonsense NM_001134738 p.Y293X 38 3766 NA NA
#3 ETS1 chr11:128426292 C T Missense NM_001143820 p.M36I 69 301 Neutral Tolerated
#3 WAS chrX:48542310 C T Missense NM_000377 p.P23L 35 675 Deletrious Damaging
#4 CTNNB1 chr3:41266101 C G Missense NM_001098210 p.S33C 45 1067 Deletrious Damaging rs121913400 COSM5677
#4 TP53 chr17:7578406 C T Missense NM_001126115 p.R43H 10 1986 Deletrious Damaging rs28934578 COSM99023
#4 PAK3 chrX:110463589 C T Missense NM_001128167 p.P517S 34 812 Deletrious Tolerated
#5 MDM4 chr1:204518424 C T Nonsense NM_002393 p.R363X 11 3274 NA NA
#5 PIK3CA chr3:178951957 G A Missense NM_006218 p.M1004I 32 3842 Deletrious Damaging COSM1420934
#6 PDE4DIP chr1:145075777 G A Missense NM_022359 p.T29M 15 1368 Neutral Damaging
#6 TP53 chr17:7579882 C T Missense NM_001126112 p.E11K 40 2495 Neutral Damaging COSM3820734
#7 LRP1B chr2:141267618 T C Missense NM_018557 p.I2759M 23 130 Neutral Tolerated
#7 SF3B1 chr2:198267361 T G Missense NM_012433 p.K666Q 37 1130 Deletrious Damaging COSM132950
#7 LIFR chr5:38482184 C T Missense NM_002310 p.R936H 25 422 Neutral Tolerated
#8 BAI3 chr6:69349139 T C Missense NM_001704 p.I191T 37 1123 Deletrious Damaging
#9 PKHD1 chr6:51618148 C A Missense NM_138694 p.S2934I 44 1167 Deletrious Damaging
#9 CRTC1 chr19:18856739 G A Missense NM_015321 p.R117Q 11 198 Neutral Damaging
#10 CSMD3 chr8:113662521 C T Missense NM_198123 p.R1021H 58 4830 Deletrious Damaging
#11 PIK3CA chr3:178936092 A G Missense NM_006218 p.E545G 20 2007 Deletrious Damaging rs121913274 COSM764
#12 MAGI1 chr3:65350349 T A Missense NM_001033057 p.Q1114H 33 457 Neutral Tolerated
#12 PIK3CA chr3:178952085 A G Missense NM_006218 p.H1047R 46 102 Neutral Damaging rs121913279 COSM775
#12 CSMD3 chr8:113421175 A C Missense NM_198123 p.L1828V 30 1584 Deletrious Tolerated
#12 TLR4 chr9:120476450 A C Missense NM_003266 p.S642R 32 3324 Deletrious Damaging
#12 PIK3R2 chr19:18277102 G C Missense NM_005027 p.E517Q 36 1571 Deletrious Damaging
#12 AMER1 chrX:63412694 T G Missense NM_152424 p.K158T 36 75 Neutral Damaging COSM287151
#13 FBXW7 chr4:153249385 G A Missense NM_018315 p.R385C 26 11650 Deletrious Damaging COSM170725
#14 ARID1A chr1:27057682 C T Nonsense NM_139135 p.Q464X 55 1053 NA NA COSM5347142
#14 LRP1B chr2:142012102 C T Missense NM_018557 p.R151K 10 516 Neutral Tolerated
#14 SMARCA4 chr19:11096976 G T Missense NM_003072 p.G156V 27 156 Neutral Damaging
#14 PPP2R1A chr19:52715982 C T Missense NM_014225 p.R183W 61 2937 Deletrious Damaging COSM51211
#15 CTNNB1 chr3:41266113 C G Missense NM_001098210 p.S37C 39 810 Deletrious Damaging rs12193403 COSM5679
#15 LPHN3 chr4:62598744 G A Missense NM_015236 p.E223K 37 1460 Deletrious Damaging
#16 ARID1A chr1:27057988 C T Nonsense NM_139135 p.Q566X 41 215 NA NA COSM1296220
#16 PIK3CA chr3:178936082 G A Missense NM_006218 p.E542K 27 1643 Neutral Damaging rs121913273 COSM760
#16 DST chr6:56507439 C T Missense NM_001723 p.E50K 34 1012 Neutral Tolerated
#16 NUMA1 chr11:71725554 G A Missense NM_001286561 p.R999C 35 519 Deletrious Damaging COSM356705
#16 ERBB2 chr17:37880998 G T Missense NM_001289937 p.G776V 27 748 Deletrious Damaging COSM18609
#17 ARID1A chr1:27058093 C T Nonsense NM_139135 p.Q601X 90 176 NA NA
#17 LPHN3 chr4:62863907 C A Missense NM_015236 p.L1039I 41 225 Neutral Damaging
#17 KDM5C chrX:53221934 G A Missense NM_001146702 p.P1378S 41 4392 Neutral Damaging
#18 PIK3CA chr3:178921555 T G Missense NM_006218 p.V346G 23 120 Deletrious Damaging COSM4714415
#18 PTEN chr10:89685307 T C Missense NM_000314 p.Y68H 67 122 Deletrious Damaging COSM5036
Var (%): variant allele frequency
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Figure 1 Representative images of OCCC for this study. (a, b) Macroscopic findings of 
left ovarian tumor. (c) Loupe image of region demarcated by the yellow square in b 
(hematoxylin & eosin staining). Area enclosed by green line is the macrodissected area. 
(d) Magnified image of the region represented by the black square in c. Tumor cells with 
abundant clear or eosinophilic cytoplasm. The scale bar is 100 mm.
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Figure 2 A dot blot of the distribution of quality of each DNA sample extracted from
FFPE samples of 29 cases, which was evaluated by the qPCR method, is shown. Cases
with relative value of > 0.3 are depicted a bold horizontal line. Both tumor and normal
samples above this line are basically accepted for NGS analysis. If either template DNA of
5 ng or 20 ng has passed the quality check, NGS analysis has been performed.
Figure 3
a b
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Figure 3 (a) A chart presents the validation by Sanger sequencing for 58 candidate somatic
mutations with > 15% variant allele frequency. (b) Filtering of NGS data. Filtering
conditions are > 20 reads in normal tissues and > 6 bp distance from amplicon boundaries
to variant position. All tumor samples have reached sequencing coverage of > 50 reads.
Figure 4
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Figure 4 A summary of 45 somatic mutations identified by NGS analysis for 409 cancer-related 
genes in 18 OCCC samples is shown. (a) Forty five somatic mutations have been identified in 34 
genes. Variant allele frequency is indicated according to the color scale. The number of variants 
is indicated the cumulative number of green boxes. (b) A bar graph represents the DNA 
substitution of 45 somatic mutations found in OCCC.
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Figure 5 A comparative representations between FFPE and FF-based NGS data from three 
OCCC cases.
Figure 5
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Figure 6 Variable histological features of OCCC cases. Each component was 
macrodissected from unstained FFPE sections for NGS. (a, b) Case #15 showing variable 
morphologies of OCCC. (a) Tumor cells with abundant eosinophilic basement membrane 
like material. (b) Tumor with solid growth. (c, d) Case #4 showing mixed epithelial tumors. 
(c) and (d) are clear cell adenocarcinoma (CC) and endometrioid adenocarcinoma (EM), 
respectively. The scale bar is 100 mm.
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